Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

  1. Herbst, R.S.
  2. Baas, P.
  3. Kim, D.-W.
  4. Felip, E.
  5. Pérez-Gracia, J.L.
  6. Han, J.-Y.
  7. Molina, J.
  8. Kim, J.-H.
  9. Arvis, C.D.
  10. Ahn, M.-J.
  11. Majem, M.
  12. Fidler, M.J.
  13. De Castro, G.
  14. Garrido, M.
  15. Lubiniecki, G.M.
  16. Shentu, Y.
  17. Im, E.
  18. Dolled-Filhart, M.
  19. Garon, E.B.
Aldizkaria:
The Lancet

ISSN: 1474-547X 0140-6736

Argitalpen urtea: 2016

Alea: 387

Zenbakia: 10027

Orrialdeak: 1540-1550

Mota: Artikulua

DOI: 10.1016/S0140-6736(15)01281-7 GOOGLE SCHOLAR